Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010010 · ClinicalTrials.gov registry record · Phase 2
Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00010010 is a Phase 2 study that has completed, run by NYU Langone Health.
The verdict
NCT00010010, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
Interventions
- DRUG exemestane
- DRUG goserelin acetate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00010010
The ClinicalTrials.gov registry entry for NCT00010010 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which exemestane is the first listed.
NCT00010010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00010010 about?
NCT00010010 is a clinical study titled "Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who hav...
What is the current status of trial NCT00010010?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06.
What interventions are being tested in trial NCT00010010?
The interventions under investigation include: exemestane (DRUG), goserelin acetate (DRUG).
Who is sponsoring clinical trial NCT00010010?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.